secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001104659-26-037760
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BrainStorm reports FY2025 net loss $10.3M; secures $2M post-year-end for Phase 3b
--------------------------------------------------------------------------------

- Cash, equivalents, restricted cash $0.3M at Dec 31, 2025; raised $2M in Feb 2026 private placements.
- Net loss $10.3M ($1.11/share) vs $11.6M ($2.31/share) in 2024; R&D spend $4.2M, G&A $5.8M.
- FDA cleared Phase 3b ENDURANCE study of NurOwn for ALS; ~200 participants, SPA and CMC aligned.
- Expanded Access Program: 5/10 patients alive, mean survival ~84 months; all 10 exceeded 5-year survival.
- Company highlights $2M strategic financing as catalyst for share re-rating and cash runway for operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465926037760/0001104659-26-037760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465926037760/tm2610751d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-037760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer